Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Curr Oncol. 2022 Jul 23;29(8):5238-5246. doi: 10.3390/curroncol29080416.
Next-generation sequencing (NGS) of tumor genomes has changed and improved cancer treatment over the past few decades. It can inform clinicians on the optimal therapeutic approach in many of the solid and hematologic cancers, including non-small lung cancer (NSCLC). Our study aimed to determine the costs of NGS assays for NSCLC diagnostics. We performed a micro-costing study of four NGS assays (Trusight Tumor 170 Kit (Illumina), Oncomine Focus (Thermo Fisher), QIAseq Targeted DNA Custom Panel and QIASeq Targeted RNAscan Custom Panel (Qiagen), and KAPA HyperPlus/SeqCap EZ (Roche)) at the StemCore Laboratories, the Ottawa Hospital, Canada. We used a time-and-motion approach to measure personnel time and a pre-defined questionnaire to collect resource utilization. The unit costs were based on market prices. The cost data were reported in 2019 Canadian dollars. Based on a case throughput of 500 cases per year, the per-sample cost for TruSight Tumor 170 Kit, QIASeq Targeted DNA Custom Panel and QIASeq Targeted RNAscan Custom Panel, Oncomine Focus, and HyperPlus/SeqCap EZ were CAD 1778, CAD 599, CAD 1100 and CAD 1270, respectively. The key cost drivers were library preparation (34-60%) and sequencing (31-51%), followed by data analysis (6-13%) and administrative support (2-7%). Trusight Tumor 170 Kit was the most expensive NGS assay for NSCLC diagnostics; however, an economic evaluation is required to identify the most cost-effective NGS assay. Our study results could help inform decisions to select a robust platform for NSCLC diagnostics from fine needle aspirates, and future economic evaluations of the NGS platforms to guide treatment selections for NSCLC patients.
在过去几十年中，肿瘤基因组的下一代测序（NGS）改变并改善了癌症治疗。它可以为许多实体瘤和血液系统癌症（包括非小细胞肺癌（NSCLC））的临床医生提供最佳治疗方法的信息。我们的研究旨在确定 NSCLC 诊断用 NGS 检测的成本。
我们在加拿大渥太华医院的 StemCore 实验室对四种 NGS 检测（Illumina 的 Trusight Tumor 170 试剂盒、Thermo Fisher 的 Oncomine Focus、Qiagen 的 QIAseq Targeted DNA Custom Panel 和 QIASeq Targeted RNAscan Custom Panel，以及 Roche 的 KAPA HyperPlus/SeqCap EZ）进行了微观成本研究。我们使用时间和动作方法来衡量人员时间，并使用预定义的问卷来收集资源利用情况。单位成本基于市场价格。成本数据以 2019 年加元报告。
基于每年 500 例的病例吞吐量，Trusight Tumor 170 试剂盒、QIASeq Targeted DNA Custom Panel 和 QIASeq Targeted RNAscan Custom Panel、Oncomine Focus 和 HyperPlus/SeqCap EZ 的每个样本成本分别为 CAD1778、CAD599、CAD1100 和 CAD1270。关键成本驱动因素是文库制备（34-60%）和测序（31-51%），其次是数据分析（6-13%）和行政支持（2-7%）。
Trusight Tumor 170 试剂盒是 NSCLC 诊断中最昂贵的 NGS 检测方法；然而，需要进行经济评估以确定最具成本效益的 NGS 检测方法。我们的研究结果可以帮助做出决策，从细针抽吸物中选择用于 NSCLC 诊断的稳健平台，并对 NGS 平台进行未来的经济评估，以指导 NSCLC 患者的治疗选择。
